It appears indeed very likely that in our patient cohort there is a stronger contribution of tumor cells to the overall TSPO signal, as GBM/IDH-wildtype gliomas (as outlined above) have an unmethylated TSPO promotor and overall higher TSPO expression levels than the IDH-mutant gliomas studied in the Zinnhardt paper [79]. Here, TSPO is linked to central nervous system cancer.